

REMARKS

This is a preliminary amendment in which the Applicants have amended claims 318 and 319. No new matter has been added.

Claims 318 and 319 have been amended to recite "endostatin." Support for this amendment can be found throughout the specification, for example, on page 48, lines 13-15.

A favorable first office action is respectfully requested.


If, for any reason, the Examiner is of the opinion that a telephone conversation with Applicants' representative would expedite prosecution, the Examiner is kindly invited to contact the undersigned at (617) 720-3500.

Please charge any fee or fee deficiency occasioned by this amendment to Deposit Account No. 23/2825.

Respectfully submitted,

*Cynthia C. Bamdad et al., Applicants*

By:

  
\_\_\_\_\_  
Timothy J. Oyer, Reg. No. 36,628  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
Tel. No.: (617) 720-3500  
Attorney's for Applicant

Docket No.: M1015/7013

Date: August 17, 2001

**MARKED-UP CLAIMS**

318. A method as in claim 316, wherein each of the first and second chemical or biological species is derived from vitronectin, and the third chemical or biological species is [angiostatin] endostatin.

319. A method as in claim 317, wherein each of the first and second chemical or biological species is vitronectin, the third chemical or biological species is [angiostatin] endostatin, and the candidate drug is a candidate for disruption of vitronectin/[angiostatin] endostatin binding.